Is it finally time to invest in Woodford Patient Capital Trust plc?

Why I’ve come out surprisingly (for me) bullish on the prospects for Woodford patient Capital Trust plc (LON: WPCT).

 

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

When investing, your capital is at risk. The value of your investments can go down as well as up and you may get back less than you put in.

Read More

The content of this article is provided for information purposes only and is not intended to be, nor does it constitute, any form of personal advice. Investments in a currency other than sterling are exposed to currency exchange risk. Currency exchange rates are constantly changing, which may affect the value of the investment in sterling terms. You could lose money in sterling even if the stock price rises in the currency of origin. Stocks listed on overseas exchanges may be subject to additional dealing and exchange rate charges, and may have other tax implications, and may not provide the same, or any, regulatory protection as in the UK.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

At 75p or so, the share price of Woodford Patient Capital Trust (LSE: WPCT) is where it was when I last wrote about the closed-ended investment fund in February. There’s been a bit of wiggling up and down, but there is evidence of basing on the chart following the plunge of around 30% since last summer. Is this a buying opportunity?

Declining net asset value

In February, the trust reported its net asset value at 91.22p per share. More recently, the figure is 82.59p per share, so with the share price near the same level, value has declined rather than increased. The fundamentals don’t support the basing action I’m seeing on the chart. Maybe the stock is in for further falls, especially if more of the underlying investments disappoint.

Neil Woodford’s public foray into the world of speculative stocks started in 2015 with the launch of FTSE 250 index-listed Woodford Patient Capital Trust, but things haven’t been going well. Last month, for example, one of the biggest holdings, Nasdaq-listed Irish biotech company Prothena, saw its stock tumbling when its most advanced treatment, Pronto, failed a trial. Prothena immediately stopped all spending on the drug that was aimed at treating AL amyloidosis.

Another example is the trust’s now-smallest holding, London-listed Midatech Pharma, an early-stage biopharmaceutical company that focuses on commercialising and developing products in oncology and other therapeutic areas. I can sum up the story of that one so far by telling you that it listed on the stock market in January 2015 with its share price close to 265p, a far cry from today’s level around 29p.

Potential billion-dollar companies?

However, Neil Woodford is reported as saying, in the teeth of such disappointments, that the trust has stakes in several companies that could be worth billions of dollars each in the next five years. On the basis of that potential, and assuming that the trust sticks with its original investments without taking any more punts on jam-tomorrow stocks, I think the lower share price makes it more attractive.

Now we are three years on from when the original investments were made, the probabilities are playing out. Losers such as Midatech become less of a problem. Already the stock has dropped to be the smallest holding in the trust – almost an insignificant weighting – and losers can only lose the trust 100% of its investment. Winners, on the other hand, are uncapped and may go on to deliver percentage returns in the thousands. Today’s losers could go also go on to win in the end.

With the benefit of hindsight, it’s easy to criticise the trust’s apparent initial scattergun approach to speculating on profitless companies.  Successful stock trader Mark Minervini advocates waiting for evidence of success in the financial figures of early-stage companies before investing, arguing that investment returns can still be spectacular with reduced exposure to firms that go on to fail — more like using a rifle than a shotgun. However, with the risks and potential now playing out in the fund’s holdings, ‘right now’ could indeed be a good time to look closely at Woodford Patient Capital Trust.

Should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice.

Kevin Godbold has no position in any of the shares mentioned. The Motley Fool UK has no position in any of the shares mentioned. Views expressed on the companies mentioned in this article are those of the writer and therefore may differ from the official recommendations we make in our subscription services such as Share Advisor, Hidden Winners and Pro. Here at The Motley Fool we believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

Investing Articles

After it crashed 25%, should I buy this former stock market darling in my Stocks and Shares ISA?

Harvey Jones has a big hole in his Stocks and Shares ISA that he is keen to fill. Should he…

Read more »

happy senior couple using a laptop in their living room to look at their financial budgets
Investing Articles

How’s the dividend forecast looking for Legal & General shares in 2025 and beyond?

As a shareholder, I like to keep track of the potential dividend returns I could make from my Legal &…

Read more »

artificial intelligence investing algorithms
Investing Articles

Could buying this stock with a $7bn market cap be like investing in Nvidia in 2010?

Where might the next Nvidia-type stock be lurking in today's market? Our writer takes a look at one candidate with…

Read more »

Investing Articles

Is GSK a bargain now the share price is near 1,333p?

Biopharma company GSK looks like a decent stock to consider for the long term, so is today's lower share price…

Read more »

Snowing on Jubilee Gardens in London at dusk
Investing Articles

Could December be a great month to buy UK shares?

Christopher Ruane sees some possible reasons to look for shares to buy in December -- but he'll be using the…

Read more »

Young mixed-race couple sat on the beach looking out over the sea
Investing Articles

Sticking to FTSE shares, I’d still aim for a £1,000 monthly passive income like this!

By investing in blue-chip FTSE shares with proven business models, our writer hopes he can build sizeable passive income streams…

Read more »

Growth Shares

BT shares? I think there are much better UK stocks for the long term

Over the long term, many UK stocks have performed much better than BT. Here’s a look at two companies that…

Read more »

British Pennies on a Pound Note
Investing Articles

After a 540% rise, could this penny share keep going?

This penny share has seen mixed fortunes in recent years. Our writer looks ahead to some potentially exciting developments in…

Read more »